Effects ofCOVID-19 on Parkinson's Disease Clinical Features: ACommunity-Based Case-ControlStudy
Effects ofCOVID-19 on Parkinson's Disease Clinical Features: ACommunity-Based Case-ControlStudy
复制标题
DOI：
10.1002/mds.28170
复制
发表时间：
2020-06-11
影响因子：
8.6
通讯作者：
Eleopra, Roberto
中科院分区：
文献类型：
--
作者：
Cilia, Roberto;Bonvegna, Salvatore;Eleopra, Roberto
到目前为止，2019年冠状病毒病（COVID-19）对帕金森病（PD）临床特征的影响还不清楚。在伦巴第大区的141名PD患者中，我们发现了12例COVID-19病例（8.5%），其平均年龄和疾病持续时间（分别为65.5和6.3年）与对照组相似。将2020年1月至2020年4月期间的临床特征变化与36名性别，年龄和疾病持续时间匹配的PD对照进行比较，使用PD严重程度指数的临床印象，运动障碍协会统一PD评定量表第II部分和第IV部分以及非运动症状量表。COVID-19组的运动和非运动症状显著恶化，三分之一的病例需要调整治疗。临床恶化可通过感染相关机制和多巴胺能治疗的药代动力学受损来解释。排尿问题和疲劳是最突出的非运动问题。认知功能轻微受累，而无自主神经功能衰竭。(c)2020国际帕金森和运动障碍协会
The impact of coronavirus disease 2019 (COVID-19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID-19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were similar to controls. Changes in clinical features in the period January 2020 to April 2020 were compared with those of 36 PD controls matched for sex, age, and disease duration using the clinical impression of severity index for PD, the Movement Disorders Society Unified PD Rating Scale Parts II and IV, and the nonmotor symptoms scale. Motor and nonmotor symptoms significantly worsened in the COVID-19 group, requiring therapy adjustment in one third of cases. Clinical deterioration was explained by both infection-related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, whereas none experienced autonomic failure. (c) 2020 International Parkinson and Movement Disorder Society